Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Paclitaxel 11Taxes 10Carboplatin 10Immunoglobulin G 6Disulfides 6Bevacizumab 6Platinum 2Gemcitabine 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1paclitaxel poliglumex 1liposomal doxorubicin 1emactuzumab 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1auricularum 1adavosertib 1X-Rays 1Watchful Waiting 1VTX-2337 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Reverse Transcriptase Polymerase Chain Reaction 1Practice Guidelines as Topic 1Observation 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brenner Tumor × VTX-2337 × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡